SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market ("Nasdaq") dated February 23, 2026, notifying the Company that the Panel determi ...

LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION [Accessibility Statement] Skip NavigationTime-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for biopharm ...

Core Insights - PolyPid Ltd. is an innovative biopharmaceutical company focused on enhancing treatment effectiveness at the point of care, with a diverse pipeline addressing unmet medical needs [4] Company Participation in Conferences - PolyPid management will participate in two investor conferences in March 2026, providing opportunities for one-on-one meetings with investors [2][3] Product Development - PolyPid's lead product, D-PLEX₁₀₀, has successfully met its primary and all key secondary endpoints in the Phase 3 SHIELD II trial aimed at preventing surgical site infections [4]

With a market cap of $154.3 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a wide range of therapeutic areas in the United States and internationally. It also engages in contract manufacturing and strategic collaborations with partners including Bristol-Myers Squibb, Astellas, BioNTech, and Boltz, PBC to advance innovative drug development. Companies valued more than $10 billion are generally classified as ...

Core Viewpoint - Scinai Immunotherapeutics Ltd. has received expanded support from the Israel Innovation Authority for its robotic aseptic fill & finish platform, with a total grant budget of NIS 5 million over two years, of which approximately 66% is non-dilutive funding [1] Group 1: Project and Funding Details - The project aims to advance a fully automated robotic-arm aseptic fill & finish system compliant with EU GMP Annex 1 standards, with validation expected to be completed in Q3 2026 [1] - The funding will support the acquisition and validation of the robotic system, enhancing Scinai's clinical manufacturing capabilities [1] Group 2: Strategic Developments - The investment is part of Scinai's strategy to modernize its CDMO capabilities following the acquisition of Recipharm Israel Ltd. and a strategic collaboration agreement with Recipharm [1] - The collaboration with Recipharm provides a pathway for clients to transition from early clinical development to late-stage and commercial manufacturing within Recipharm's global network [1] Group 3: Operational Enhancements - Robotic aseptic processing is expected to reduce human intervention, enhance reproducibility, and strengthen contamination control in sterile manufacturing [1] - The new platform will support complex biologics programs and align with the expansion of Scinai's development and manufacturing footprint [1] Group 4: Future Opportunities - The company is monitoring a potential new IIA program to support industrial CAPEX investments, which could further enhance capabilities at its Yavne small-molecule site [1]

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 am Eastern TimeToll Free:1-800-7 ...

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Conference, t ...

Core Insights - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease and Parkinson's disease [1][3] - The company will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Anavex Life Sciences Corp. is publicly traded on Nasdaq under the ticker AVXL and is dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [3] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [3] - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [3]

CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the Citizens Life Sciences Conference in Miami Beach, FL on Wednesday, March 11, 2026, at 9:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link ...

WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio ...